Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Ciani, Oriana
Buyse, Marc
Garside, Ruth
Peters, Jaime
Saad, Everardo D.
Stein, Ken
and
Taylor, Rod S.
2015.
Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
Journal of Clinical Epidemiology,
Vol. 68,
Issue. 7,
p.
833.
Chibaudel, Benoist
Bonnetain, Franck
Tournigand, Christophe
de Larauze, Marine Hug
de Gramont, Armand
Laurent-Puig, Pierre
Paget, Jérôme
Hadengue, Alexandra
Notelet, Dominique
Benetkiewicz, Magdalena
André, Thierry
and
de Gramont, Aimery
2015.
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
BMC Cancer,
Vol. 15,
Issue. 1,
Aprile, Giuseppe
Fontanella, Caterina
Bonotto, Marta
Rihawi, Karim
Lutrino, Stefania Eufemia
Ferrari, Laura
Casagrande, Mariaelena
Ongaro, Elena
Berretta, Massimiliano
Avallone, Antonio
Rosati, Gerardo
Giuliani, Francesco
and
Fasola, Gianpiero
2015.
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
Oncotarget,
Vol. 6,
Issue. 30,
p.
28716.
Drummond, Michael
2015.
When do performance-based risk-sharing arrangements make sense?.
The European Journal of Health Economics,
Vol. 16,
Issue. 6,
p.
569.
Amur, S
LaVange, L
Zineh, I
Buckman‐Garner, S
and
Woodcock, J
2015.
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.
Clinical Pharmacology & Therapeutics,
Vol. 98,
Issue. 1,
p.
34.
Vitry, Agnes
Mintzes, Barbara
and
Lipworth, Wendy
2016.
Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.
Journal of Pharmaceutical Policy and Practice,
Vol. 9,
Issue. 1,
Burke, Harry B.
2016.
Predicting Clinical Outcomes Using Molecular Biomarkers.
Biomarkers in Cancer,
Vol. 8,
Issue. ,
p.
BIC.S33380.
Rognoni, Carla
Ciani, Oriana
Sommariva, Silvia
Facciorusso, Antonio
Tarricone, Rosanna
Bhoori, Sherrie
and
Mazzaferro, Vincenzo
2016.
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.
Oncotarget,
Vol. 7,
Issue. 44,
p.
72343.
Ciani, Oriana
Buyse, Marc
Drummond, Mike
Rasi, Guido
Saad, Everardo D.
and
Taylor, Rod S.
2016.
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.
Nature Reviews Drug Discovery,
Vol. 15,
Issue. 7,
p.
516.
Friedrich, Daniel R.
2016.
Lebensqualität in der Medizin.
p.
121.
Xie, Wanling
Regan, Meredith M.
Buyse, Marc
Halabi, Susan
Kantoff, Philip W.
Sartor, Oliver
Soule, Howard
Clarke, Noel W.
Collette, Laurence
Dignam, James J.
Fizazi, Karim
Paruleker, Wendy R.
Sandler, Howard M.
Sydes, Matthew R.
Tombal, Bertrand
Williams, Scott G.
and
Sweeney, Christopher J.
2017.
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
Journal of Clinical Oncology,
Vol. 35,
Issue. 27,
p.
3097.
Laporte, S.
Chapelle, C.
Bertoletti, L.
Ollier, E.
Zufferey, P.
Lega, J.‐C.
Merah, A.
Décousus, H.
Schulman, S.
Meyer, G.
Cucherat, M.
and
Mismetti, P.
2017.
Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta‐analysis of randomized controlled trials.
Journal of Thrombosis and Haemostasis,
Vol. 15,
Issue. 8,
p.
1547.
Ciani, Oriana
Buyse, Marc
Drummond, Michael
Rasi, Guido
Saad, Everardo D.
and
Taylor, Rod S.
2017.
Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.
Value in Health,
Vol. 20,
Issue. 3,
p.
487.
Woolacott, Nerys
Corbett, Mark
Jones-Diette, Julie
and
Hodgson, Robert
2017.
Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview.
Journal of Clinical Epidemiology,
Vol. 90,
Issue. ,
p.
108.
Michiels, Stefan
Saad, Everardo D.
and
Buyse, Marc
2017.
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
Drugs,
Vol. 77,
Issue. 7,
p.
713.
Saad, E.D.
and
Buyse, M.
2017.
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
Annals of Oncology,
Vol. 28,
Issue. 11,
p.
2629.
Devlin, Nancy J.
and
Lorgelly, Paula K.
2017.
QALYs as a measure of value in cancer.
Journal of Cancer Policy,
Vol. 11,
Issue. ,
p.
19.
Hettle, Robert
Corbett, Mark
Hinde, Sebastian
Hodgson, Robert
Jones-Diette, Julie
Woolacott, Nerys
and
Palmer, Stephen
2017.
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Health Technology Assessment,
Vol. 21,
Issue. 7,
p.
1.
Hackshaw, Allan
2018.
Practical Management of Thyroid Cancer.
p.
339.
Savina, Marion
Gourgou, Sophie
Italiano, Antoine
Dinart, Derek
Rondeau, Virginie
Penel, Nicolas
Mathoulin-Pelissier, Simone
and
Bellera, Carine
2018.
Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Critical Reviews in Oncology/Hematology,
Vol. 123,
Issue. ,
p.
21.